Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
McKesson
Harvard Business School
Boehringer Ingelheim
Colorcon

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR ESTRACE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Estrace

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00114517 ↗ ELITE: Early Versus Late Intervention Trial With Estradiol Completed National Institute on Aging (NIA) Phase 2/Phase 3 2004-07-01 The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00114517 ↗ ELITE: Early Versus Late Intervention Trial With Estradiol Completed University of Southern California Phase 2/Phase 3 2004-07-01 The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00115024 ↗ EPAT: Estrogen in the Prevention of Atherosclerosis Trial Completed Mead Johnson Nutrition Phase 2/Phase 3 1994-04-01 The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
NCT00115024 ↗ EPAT: Estrogen in the Prevention of Atherosclerosis Trial Completed National Institute on Aging (NIA) Phase 2/Phase 3 1994-04-01 The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Estrace

Condition Name

Condition Name for Estrace
Intervention Trials
Atrophic Vaginitis 3
Polycystic Ovary Syndrome 2
Vaginal Atrophy 2
Menopause 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Estrace
Intervention Trials
Atrophy 7
Vaginitis 4
Polycystic Ovary Syndrome 3
Pelvic Organ Prolapse 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Estrace

Trials by Country

Trials by Country for Estrace
Location Trials
United States 110
Chile 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Estrace
Location Trials
California 8
Pennsylvania 7
Virginia 6
North Carolina 6
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Estrace

Clinical Trial Phase

Clinical Trial Phase for Estrace
Clinical Trial Phase Trials
Phase 4 6
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Estrace
Clinical Trial Phase Trials
Completed 17
Recruiting 5
Not yet recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Estrace

Sponsor Name

Sponsor Name for Estrace
Sponsor Trials
National Institute of Mental Health (NIMH) 3
University of North Carolina, Chapel Hill 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Estrace
Sponsor Trials
Other 31
Industry 15
NIH 10
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
AstraZeneca
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.